Broncho-munal n caps. 3.5mg 10 pc

$11.62

Broncho-munal n caps. 3.5mg 10 pc

Quantity:

Description

Composition
Active substance:
1 capsule contains: standardized lyophilizate bacterial lysates (OM-85) – 20.0 mg (active substance “OM-85” comprises a lyophilized lysates of bacteria – 3.50 mg (Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae , Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis).
Excipients:
Propyl gallate (anhydrous), sodium glutamate (anhydrous), magnesium stearate, pregelatinized starch, mannitol. capsule shell: indigotine E132, E171 titanium dioxide, gelatin.
Description:
Hard gelatin capsule size 3 № lid blue opaque white opaque body.
The contents of the capsule: light beige powder.
Product form:
Capsules 3.5 mg
10 capsules in Al / PVC blister 1 or 3 in the blister cardboard pack together with instructions for use.
Contraindications
Increased sensitivity to the drug; pregnancy; breastfeeding; Children up to age 6 months.
Dosage
3.5 mg
Indications
Broncho-munal® P is used in children aged 6 months to 12 years: in the complex therapy of acute respiratory tract infections; for the prevention of recurrent respiratory tract infections and acute exacerbations of chronic bronchitis.
Interaction with other drugs
There was no drug interactions with other drugs. The formulation may be applied simultaneously with other drugs, including antibiotics.
Overdose
There are no reports of toxicity due to drug overdose. The nature of the drug Broncho-munal® II and the results of the study of toxicity in animals indicate that the overdose is unlikely.
pharmachologic effect
Pharmacological group:
Immunostimulatory agent.
Pharmacodynamics:
Broncho-drug munal® P immunostimulant effect, enhancing immunity against respiratory infections.
Patients receiving the drug Broncho-munal® P, enhances the protective properties of the organism against bacteria and viruses.
Upon receiving the capsule bacterial lysate accumulates in Peyer’s patch mucosa of the gastrointestinal tract, in particular located in the small intestine. Antigen presenting cells in Peyer’s patches are activated by bacterial lysate and subsequently stimulate other types of cells (B lymphocytes) responsible for specific immunity. This leads to an increase in the number of circulating B-lymphocytes, which leads to an increase in production of polyclonal antibodies, especially IgG and serum IgA, secretory airway mucosa and salivary glands.
Also, the drug has an effect on non-specific immunity by stimulating leukocytes, which is characterized by an increase in the number of cells of the myeloid and lymphoid series, as well as a selective increase in the expression of receptors on their surface.
Patients receiving the drug Broncho-munal® P, enhances the protective properties of the organism against bacteria and viruses.
Clinically Broncho-munal® P reduces the incidence of acute respiratory tract infection, reduce the duration of the flow, reduces the likelihood of acute exacerbation of chronic bronchitis, as well as increases the resistance to infections of the respiratory system. This reduces the need for use of other drugs, particularly antibiotics.
Pregnancy and breast-feeding
Animal studies revealed no adverse effects on pregnancy. The safety and efficacy of the drug during pregnancy and lactation has not been studied, so the use of the drug Broncho-munal® P during pregnancy and breast-feeding is contraindicated.
Conditions of supply of pharmacies
Without recipe.
side effects
Broncho-n munal® generally well tolerated. Most adverse reactions are related to the general category of moderate or moderately severe manifestations. The most frequent manifestation of the side effects is a disorder of the gastrointestinal tract, skin reactions and disorders of the respiratory system.
According to the World Health Organization (WHO), undesirable effects are classified according to their rate of development as follows: very common (> 1/10); common (> 1/100,
special instructions
In order to avoid an overdose of children from 6 months to 12 years should not use the drug Broncho-munal® capsules 7mg intended for adults. Possible manifestations of hypersensitivity reactions to the drug. In the case of persistent gastrointestinal disorders, skin reactions, disorders of the respiratory or other symptoms of intolerance to the drug to stop the drug and seek medical advice.
The drug has no effect on the ability to focus and management of vehicles, machinery.
Storage conditions
At a temperature of 15 to 25 C.
The drug should be stored out of reach of children.
Dosing and Administration
The drug is taken 1 capsule daily in the morning on an empty stomach, 30 minutes before a meal. Children under 3 years of age or if the child is difficult to swallow the capsule, it should be open, the contents mixed with a small amount of liquid (tea, milk, or juice).
For the prevention of recurrent respiratory infections and exacerbations of chronic bronchitis three courses of the drug is used for 10 days, the interval between courses 20 days.
In the combined therapy of acute respiratory tract infections the drug is used until symptoms disappear, but at least 10 days. During the antibiotic Broncho-munal® P to be taken in conjunction with antibiotic treatment begins.
Subsequent 2 months possibly prophylactic drug: courses for 10 days, the interval between courses 20 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Sandoz UTS

There are no reviews yet.

Add your review